在快速回调一周后，今天港股创新药公司又迎来了反攻，和铂医药、维立志博、信达生物、百济神州、石药集团、三 生制药等个股大涨，港股创新药ETF（513120）涨超4%。 近期，又有创新药公司冲击港股IPO。 格隆汇获悉，应世生物于8月25日递表港交所，以18A章规则寻求港股上市，由中信证券和建银国际担任联席保荐人。 应世生物专注于肿瘤治疗领域的创新药研发，与近期众多创新药公司BD的趋势相反，应世生物的核心产品是由外部收 购而来，公司预计于2025年底或2026年初提交首个NDA申请，目前仍然面临一定的不确定性。 01 王博士先后获得郑州大学河南医学院获得医学学士学位、美国弗吉尼亚理工学院和州立大学获得博士学位，后在约翰 霍普金斯医学院完成了博士后研究。 60后医生转型做药物研发，刘永好、复星医药参投 应世生物成立于2017年，总部位于南京市江北新区，公司是一家处于临床后期阶段的生物科技公司，专注于解决由肿 瘤防御所引起的耐药问题。 目前，王在琪博士、曹飞先生、张宁博士及Yang Weiping博士通过一致行动协议，通过直接及间接的方式，合计控制 公司约26.51%的股份。 应世生物成立以来获得过6轮融资。就在递表 ...

Core Viewpoint - InxMed Limited is a late-stage clinical biotechnology company focused on improving cancer treatment options, particularly addressing drug resistance caused by tumor defenses [1][2]. Group 1: Company Overview - InxMed Limited was established in 2017 and is currently in the late clinical stage of development [1]. - The company aims to tackle core challenges in cancer treatment, specifically targeting key signaling pathways such as FAK and integrin pathways that play critical roles in tumor cell survival [1][2]. Group 2: Product Pipeline - The product pipeline includes: - Ifebemtinib, a highly selective FAK inhibitor nearing commercialization, which has received breakthrough therapy designation from NMPA for three indications and fast track designation from FDA for one indication, indicating its potential as a cornerstone therapy for cancer [2]. - IN10028, a second-generation selective FAK inhibitor aimed at maintaining a leading position in the market [2][3]. - Three innovative antibody-drug conjugates (ADCs): - OMTX705, targeting CAFs in the tumor microenvironment, showing synergy with anti-PD-1 therapies [2]. - IN30758, focusing on upstream FAK signaling pathways, which works synergistically with FAK inhibitors [2]. - IN30778, targeting unique tumor-associated antigens expressed in various solid tumors [2]. Group 3: Financial Performance - Financial results for the fiscal years ending March 31 are as follows: - 2023: Net income of approximately -392,000 RMB - 2024: Net income of approximately 2.472 million RMB - 2025: Net income of approximately 1.603 million RMB - The company reported losses of approximately -209 million RMB, -185 million RMB, and -3.369 million RMB for the same periods [3].

Core Viewpoint - InxMed Limited, a late-stage biotech company focused on improving cancer treatment, has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and CCB International as joint sponsors [1][3]. Company Overview - InxMed Limited was established in 2017 and aims to address the core challenges of cancer treatment, particularly drug resistance caused by tumor defenses [1][3]. - The company focuses on key signaling pathways common across various tumor types, especially the FAK and integrin pathways, which play critical roles in tumor cell survival [3]. Product Pipeline - The product pipeline includes: - **Ifebemtinib**: A highly selective FAK inhibitor nearing commercialization, currently undergoing multiple clinical development projects in China. It has received breakthrough therapy designation from NMPA for three indications and fast track designation from FDA for one indication, indicating its potential as a cornerstone therapy for cancer [3][4]. - **IN10028**: A second-generation selective FAK inhibitor aimed at maintaining a leading position in the field, with an IND application expected to be submitted by 2025 and first human clinical trials anticipated to start in Q1 2026 [4]. - **Three innovative antibody-drug conjugates (ADCs)**: - **OMTX705**: Targets CAFs in the tumor microenvironment and shows synergy with various therapies, including anti-PD-1 [3]. - **IN30758**: Focuses on upstream signaling pathways of FAK, showing synergy with FAK inhibitors [3]. - **IN30778**: Targets unique tumor-associated antigens that are highly expressed in various solid tumors [3]. Financial Overview - Financial performance for the three months ending March 31 for the years 2023 to 2025 shows: - Net other income/loss: -392 thousand RMB in 2023, 2,472 thousand RMB in 2024, and 397 thousand RMB in 2025 [5]. - Administrative expenses: -38,104 thousand RMB in 2023, -45,071 thousand RMB in 2024, and -9,866 thousand RMB in 2025 [5]. - R&D expenses: -135,517 thousand RMB in 2023, -99,999 thousand RMB in 2024, and -17,207 thousand RMB in 2025 [5]. - Operating loss: -174,013 thousand RMB in 2023, -142,598 thousand RMB in 2024, and -26,676 thousand RMB in 2025 [5]. - Net loss for the year: -209,249 thousand RMB in 2023, -184,619 thousand RMB in 2024, and -29,712 thousand RMB in 2025 [5].

智通财经APP获悉，据港交所8月25日披露，应世生物(InxMed Limited)向港交所主板递交上市申请，中信证券和建银国际为其联席保荐人。据招股书，应世 生物是一家于2017年成立的处于临床后期阶段的生物科技公司，致力于改进目前疗效有限的肿瘤治疗方案。公司的使命是解决肿瘤治疗的核心挑战-由肿瘤 防御所引起的耐药。 招股书显示，应世生物聚焦于多种肿瘤类型共有拥有的关键讯号传导枢纽，尤其是 FAK及整合素通路，它们在肿瘤细胞存活中发挥关键作用，并导致不同 治疗案失败。同时，应世生物通过靶向CAFs来拆除肿瘤细胞周围的保护屏障。通过靶向耐药关键通路，应世生物为重塑癌症治疗合理用药方案，开辟治疗 创新的新前沿。 据应世生物在招股书中或存在的风险因素中提到，公司在很大程度上依赖于候选产品的成功。倘若无法成功完成临床开发或实现临床阶段及临床前阶段产品 线的商业化，或者倘若在上述任何环节遇到重大延误或成本超支，则公司的业务及前景可能会受到重大不利影响。 截至最后实际可行日期，应世生物的产品管线包括：(i)核心产品ifebemtinib (一种接近商业化的高选择性FAK抑制剂)，其正在中国进行多项临床开发项目;其 针对 ...